Hu, Zhongyi
Yuan, Jiao
Long, Meixiao
Jiang, Junjie
Zhang, Youyou
Zhang, Tianli
Xu, Mu
Fan, Yi http://orcid.org/0000-0002-6290-0595
Tanyi, Janos L.
Montone, Kathleen T.
Tavana, Omid
Chan, Ho Man
Hu, Xiaowen http://orcid.org/0000-0002-3269-4356
Vonderheide, Robert H. http://orcid.org/0000-0002-7252-954X
Zhang, Lin http://orcid.org/0000-0003-1998-0611
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01CA210944, R01CA229803, P30CA016520, R01CA225929, R01CA190415, R01CA142776)
Article History
Received: 14 January 2021
Accepted: 1 October 2021
First Online: 13 December 2021
Competing interests
: L.Z. and X.H. report having received research funding from AstraZeneca, Bristol-Myers Squibb/Celgene and Prelude Therapeutics. R.H.V. is an inventor on a licensed patent relating to cancer cellular immunotherapy and receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody. O.T. and H.M.C. are employees of AstraZeneca. The remaining authors declare no competing interests.